Stockreport

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech, Inc. - Common Shares  (EDSA) 
PDF 1.0% Formulation Reached Primary Endpoint with Statistical SignificanceFull Analysis Identified Additional Efficacy SignalsTORONTO, ON / ACCESSWIRE / November 20, 2023 / [Read more]